Page last updated: 2024-10-25

clonidine and Chronic Pain

clonidine has been researched along with Chronic Pain in 21 studies

Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.

Chronic Pain: Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.

Research Excerpts

ExcerptRelevanceReference
"Eperisone, an analgesic and centrally acting muscle relaxant has been in use for the treatment of low back pain (LBP)."8.93Clinical efficacy and safety of eperisone for low back pain: A systematic literature review. ( Ali Kareem, S; Bavage, S; Dhadde, SB; Durg, S, 2016)
" Clonidine is better than zopiclone for insomnia treatment in chronic pain patients."8.12Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. ( Bamgbade, DO; Bamgbade, OA; Fadire, A; Mumporeze, L; Murphy-Akpieyi, O; Soni, NK; Tai-Osagbemi, J, 2022)
"Chronic pain is a major health issue and most patients suffer from spontaneous pain."5.42Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice. ( Feng, ZH; Li, XY; Liu, L; Mei, SH; Wang, M; Wang, Y; Wang, YJ; Zuo, ZX, 2015)
"Clonidine is a presynaptic alpha-2-adrenergic receptor agonist that has been used for many years to treat hypertension and other conditions, including chronic pain."5.22Topical clonidine for neuropathic pain in adults. ( Dobrogowski, J; Garlicki, J; Jakowicka-Wordliczek, J; Serednicki, WT; Wordliczek, J; Woron, J; Wrzosek, A; Zajaczkowska, R, 2022)
"Eperisone, an analgesic and centrally acting muscle relaxant has been in use for the treatment of low back pain (LBP)."4.93Clinical efficacy and safety of eperisone for low back pain: A systematic literature review. ( Ali Kareem, S; Bavage, S; Dhadde, SB; Durg, S, 2016)
"Clonidine is a presynaptic alpha-2-adrenergic receptor agonist used for many years to treat hypertension and other conditions, including chronic pain."4.91Topical clonidine for neuropathic pain. ( Dobrogowski, J; Jakowicka-Wordliczek, J; Wordliczek, J; Woron, J; Wrzosek, A, 2015)
" Clonidine is better than zopiclone for insomnia treatment in chronic pain patients."4.12Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. ( Bamgbade, DO; Bamgbade, OA; Fadire, A; Mumporeze, L; Murphy-Akpieyi, O; Soni, NK; Tai-Osagbemi, J, 2022)
"Multimodal IT treatment with morphine, bupivacaine and clonidine is effective and safe for treating refractory cancer pain in the terminal phase of disease."3.85Multimodal intrathecal analgesia in refractory cancer pain. ( Kallewaard, JW; Kramp-Hendriks, BJ; Mastenbroek, TC; Vonk, JM, 2017)
"Clonidine is a central alpha(2)-agonist antihypertensive used widely for opioid/alcohol withdrawal, attention deficit hyperactivity disorder and chronic pain management."3.83Intrathecal Clonidine Pump Failure Causing Acute Withdrawal Syndrome With 'Stress-Induced' Cardiomyopathy. ( Graudins, A; Lee, HM; Ruggoo, V, 2016)
" An antiallodynic topical combination of apraclonidine + lisofylline was also found to effectively relieve depressed postocclusive reactive hyperemia in CPIP rats (N = 61) and to increase formazan production in postischemic tissues (skin and muscle) (N = 56)."3.80Topical combinations to treat microvascular dysfunction of chronic postischemia pain. ( Abaji, R; Coderre, TJ; Laferrière, A; Ragavendran, JV; Tsai, CY, 2014)
"Chronic pain may be accompanied by hyperalgesia and allodynia, and analgesic interventions may reduce these hypersensitivity phenomena."2.80Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome. ( Eisenach, JC; North, J; Rauck, RL, 2015)
"The frequency of neuropathic pain was assessed using the Douleur Neuropathique 4-question survey (DN4) in the first and second postoperative months."2.78Effect of the addition of clonidine to locally administered bupivacaine on acute and chronic postmastectomy pain. ( Abdel-Ghaffar, HS; Mohamed, SA, 2013)
"It is essential to find good postoperative pain control strategies that facilitate early mobility, early recovery, and early hospital discharge with minimal side effects on the mother and infant."2.66Strategies of analgesic treatment after cesarean delivery. Current state and new alternatives. ( Arroyo-Fernández, FJ; Calderón Seoane, JE; Torres Morera, LM, 2020)
"Chronic pelvic pain is a common and debilitating condition; its aetiology is multifactorial, involving social, psychological and biological factors."2.50Non-surgical interventions for the management of chronic pelvic pain. ( Cheong, YC; Smotra, G; Williams, AC, 2014)
"Recent awareness that chronic pain may occur after childbirth has prompted clinicians and researchers to investigate this topic."2.49Chronic pain after childbirth. ( Bollag, L; Landau, R; Ortner, C, 2013)
"Chronic pain is a major health issue and most patients suffer from spontaneous pain."1.42Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice. ( Feng, ZH; Li, XY; Liu, L; Mei, SH; Wang, M; Wang, Y; Wang, YJ; Zuo, ZX, 2015)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's17 (80.95)24.3611
2020's4 (19.05)2.80

Authors

AuthorsStudies
Wu, YJ1
Guernon, J1
McClure, A1
Luo, G1
Rajamani, R1
Ng, A1
Easton, A1
Newton, A1
Bourin, C1
Parker, D1
Mosure, K1
Barnaby, O1
Soars, MG1
Knox, RJ1
Matchett, M1
Pieschl, R1
Herrington, J1
Chen, P1
Sivarao, DV1
Bristow, LJ1
Meanwell, NA1
Bronson, J1
Olson, R1
Thompson, LA1
Dzierba, C1
Salihovic, M1
Rijavec, B1
Muratagic, A1
Blagus, R1
Puh, U1
Bamgbade, OA1
Tai-Osagbemi, J1
Bamgbade, DO1
Murphy-Akpieyi, O1
Fadire, A1
Soni, NK1
Mumporeze, L1
Serednicki, WT1
Wrzosek, A2
Woron, J2
Garlicki, J1
Dobrogowski, J2
Jakowicka-Wordliczek, J2
Wordliczek, J2
Zajaczkowska, R1
Arroyo-Fernández, FJ1
Calderón Seoane, JE1
Torres Morera, LM1
Mastenbroek, TC1
Kramp-Hendriks, BJ1
Kallewaard, JW1
Vonk, JM1
Hao, D1
Olugbodi, A1
Udechukwu, N1
Donato, AA1
Maranto, CJ1
Strickland, NR1
Goree, JH1
Landau, R1
Bollag, L1
Ortner, C1
De Andres, J1
Asensio-Samper, JM1
Fabregat-Cid, G1
Cheong, YC1
Smotra, G1
Williams, AC1
Laferrière, A1
Abaji, R1
Tsai, CY1
Ragavendran, JV1
Coderre, TJ1
Rauck, RL1
North, J1
Eisenach, JC1
Lee, HM1
Ruggoo, V1
Graudins, A1
Zuo, ZX1
Wang, YJ1
Liu, L1
Wang, Y1
Mei, SH1
Feng, ZH1
Wang, M1
Li, XY1
Bavage, S1
Durg, S1
Ali Kareem, S1
Dhadde, SB1
Park, SC1
Kim, KH1
Rossi, M1
Ianigro, G1
Liberatoscioli, G1
Di Castelnuovo, A1
Grimani, V1
Garofano, A1
Camposarcone, N1
Nardi, LF1
Jackson, TP1
Lonergan, DF1
Todd, RD1
Martin, PR1
Mohamed, SA1
Abdel-Ghaffar, HS1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of the Effectiveness of Pulsed Radiofrequency Therapy and Canal Adductor Blockade for Chronic Pain and Functioning in Knee Osteoarthritis[NCT05962463]128 participants (Anticipated)Observational2023-12-20Not yet recruiting
Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients[NCT05618002]150 participants (Anticipated)Observational2022-11-08Recruiting
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Topical Gel, 0.1% With Placebo in the Management of Pain Associated With Painful Diabetic Neuropathy[NCT00695565]Phase 2180 participants (Actual)Interventional2008-05-31Completed
A Multicenter Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group Study to Determine the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy[NCT02068027]Phase 2260 participants (Actual)Interventional2014-03-31Completed
Diabetic Neuropathic Pain Topical Treatment- Comparative Study[NCT00661063]Phase 3200 participants (Anticipated)Interventional2008-04-30Not yet recruiting
Comparison of PECS II Block and Combined Serratus Anterior Plane Block to Reduce Acute Pain After Mastectomy[NCT05961735]60 participants (Anticipated)Observational2023-08-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in the Brief Pain Inventory (BPI) Severity Scale at Week 12; mLOCF Imputation

"The Brief Pain Inventory was completed by the subject at clinic visits. The Severity Scale (of 0 to 40) is a composite score, which is the sum of the individual ratings for worst pain, least pain, average pain, and current pain. Each individual question is rated on a scale of 0 to 10, where 0 indicates No Pain and 10 indicates Pain as bad as you can imagine. The change in pain severity is represented as Week 12 minus Baseline, so greater negative numbers represent greater improvement (pain relief)." (NCT00695565)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Placebo Gel-7.9
Clonidine Topical Gel (ARC-4558)-9.6

Change From Baseline in the Brief Pain Inventory Functional Interference Scale at Week 12; mLOCF Imputation

"The Brief Pain Inventory was completed by the subject at clinic visits. The Functional Interference Scale (of 0 to 70) is a composite score that measures the degree to which pain interferes with mood, walking, work, relationships, sleep, general activity, and enjoyment of life. The composite score is a sum of the seven individual question scores. Each individual question is rated in reference to pain over the past 24 hours on a scale of 0 to 10, where 0 indicates that pain does not interfere and 10 indicates that pain completely interferes with that function, so lower scores represent better outcomes on this scale.~The change in functional interference is represented as Week 12 minus Baseline, so greater negative numbers represent more improvement." (NCT00695565)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Placebo Gel-15.1
Clonidine Topical Gel (ARC-4558)-17.3

Change From Baseline to Week 12 in Overall Quality of Sleep (Chronic Pain Sleep Inventory)

Subjects rated overall quality of sleep over the past week using a 100 mm Visual Analog Scale (VAS) where 100=Excellent and 0=Very Poor. This scale was completed during clinic visits. Change from Baseline is a positive value where quality of sleep improved. (NCT00695565)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Placebo Gel17.7
Clonidine Topical Gel (ARC-4558)19.2

Change From Baseline to Week 12 in the Anxiety Score of the Hospital Anxiety and Depression Scale (HADS)

The HADS was completed at the Baseline and Week 12 clinic visits. The Anxiety Score component of the HADS includes 7 questions, each with 4 possible answer choices (rated 0 to 3). The composite score is created by adding the scores of the 7 individual questions. A score of 0 to 7 is Normal, 8-10 indicates Mild Anxiety, 11-14 indicates Moderate Anxiety, and 15-21 indicates Severe Anxiety. The change from Baseline is calculated as the Week 12 composite score minus the Baseline composite score. (NCT00695565)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Placebo Gel-0.6
Clonidine Topical Gel (ARC-4558)-1.1

Change From Baseline to Week 12 in the Depression Score of the Hospital Anxiety and Depression Scale (HADS)

The HADS was completed at the Baseline and Week 12 clinic visits. The Depression Score component of the HADS includes 7 questions, each with 4 possible answer choices (rated 0 to 3). The composite score is created by adding the scores of the 7 individual questions. A score of 0 to 7 is Normal, 8-10 indicates Mild Depression, 11-14 indicates Moderate Depression, and 15-21 indicates Severe Depression. The change from Baseline is calculated as the Week 12 composite score minus the Baseline composite score. (NCT00695565)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Placebo Gel-0.4
Clonidine Topical Gel (ARC-4558)-0.9

Change From Baseline to Week 12 in the McGill Pain Questionnaire (Short Form) Total Score

The McGill Pain Questionnaire asks subjects to rate 15 different kinds of pain, each on a scale of 0 to 3 (0=None, 1=Mild, 2=Moderate, 3=Severe). The total score is a sum of the individual ratings and has a range from 0 to 45, where higher numbers indicate more pain. The 15 types of pain assessed are throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting, tiring-exhausting, sickening, fearful, and punishing-cruel. This scale was completed at the Baseline and Week 12 clinic visits. The change from Baseline is calculated as the Week 12 total score minus the Baseline total score, so greater negative numbers indicate more improvement (pain relief). (NCT00695565)
Timeframe: Baseline and Week 12

Interventionunits on a scale (Mean)
Placebo Gel-7.3
Clonidine Topical Gel (ARC-4558)-8.7

Change From Baseline to Week 12 in the Worst Daily Pain NPRS Score; mLOCF Imputation

"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale. Subjects were asked to record the worst pain in their feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain. The change in pain is represented as Week 12 minus Baseline, so greater negative numbers represent greater improvement (greater pain relief)." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)

Interventionunits on a scale (Mean)
Placebo Gel-2.1
Clonidine Topical Gel (ARC-4558)-2.5

Percentage of Subjects Who Experience at Least 30% Reduction in Average Daily Pain From Baseline; mLOCF Imputation

"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)

Interventionpercentage of subjects (Number)
Placebo Gel47
Clonidine Topical Gel (ARC-4558)52

Percentage of Subjects Who Experience at Least 50% Reduction in Average Daily Pain From Baseline; mLOCF Imputation

"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)

Interventionpercentage of subjects (Number)
Placebo Gel32
Clonidine Topical Gel (ARC-4558)37

Change From Baseline in Average Daily Pain NPRS Score for Each Week of Treatment; mLOCF Imputation

"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain. A weekly average was calculated from the daily scores for each week. The change in pain is represented as the average weekly score minus Baseline, so greater negative numbers represent more improvement (more pain relief)." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Weeks 1 through 12 (weekly averages)

,
Interventionunits on a scale (Mean)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12
Clonidine Topical Gel (ARC-4558)-0.7-1.0-1.5-1.6-1.7-1.8-2.1-2.2-2.3-2.4-2.3-2.4
Placebo Gel-0.6-1.0-1.2-1.5-1.7-1.8-1.8-1.9-1.9-1.9-1.9-1.9

Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation

"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS) through Day 84. Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain.~The change in pain is represented as Week 12 minus Baseline, so greater negative numbers represent more improvement (more pain relief)." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (Average of Days 78 to 84)

,
Interventionunits on a scale (Mean)
All subjectsCapsaicin response ≥ 2
Clonidine Topical Gel (ARC-4558)-2.4-2.7
Placebo Gel-1.9-1.5

Change in Blood Pressure From Baseline to Week 12

Systolic and Diastolic Blood Pressure were measured at clinic visits. This outcome assesses the change in blood pressure from Baseline to Week 12 of treatment. (NCT00695565)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
Change in Systolic BPChange in Diastolic BP
Clonidine Topical Gel (ARC-4558)1.01.0
Placebo Gel-0.4-0.2

Clinician Global Impression of Change (CGIC) at Week 12

At Week 12, the Investigator was asked to independently rate the subject's total improvement relative to Baseline, whether or not, in their judgement, it was due entirely to study drug treatment or not. Answer choices were: (+3) very much improved, (+2) much improved, (+1) minimally improved, (0) no change, (-1) minimally worse, (-2) much worse, (-3) very much worse. (NCT00695565)
Timeframe: Week 12

,
Interventionpercentage of subjects (Number)
Very Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseVery Much Worse
Clonidine Topical Gel (ARC-4558)16.530.624.727.11.20
Placebo Gel5.838.427.925.62.30

Patient Global Impression of Change (PGIC) at Week 12

At Week 12 the subject was asked to rate their total improvement relative to Baseline, whether or not, in their judgement, it was due entirely to study drug treatment or not. Answer choices were: (+3) very much improved, (+2) much improved, (+1) minimally improved, (0) no change, (-1) minimally worse, (-2) much worse, (-3) very much worse. (NCT00695565)
Timeframe: Week 12

,
Interventionpercentage of subjects (Number)
Very Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseVery Much Worse
Clonidine Topical Gel (ARC-4558)21.227.128.222.41.20
Placebo Gel11.832.931.821.21.21.2

Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score

"The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days]) in the Numeric Pain Rating Scale score assessing the average pain in the past 24 hours in the painful areas of the feet averaged over Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the primary efficacy endpoint, the mean change in pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model." (NCT02068027)
Timeframe: The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days])

Interventionunits on a scale (Mean)
Clonidine Gel 0.1%-1.6
Placebo-1.6

Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores

"The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (worst score from Day -14 to Day -8) to End-of-Treatment (worst score during Days 78 to 84 [±3 days]) in the Numeric Pain Rating Scale score assessing the worst pain in the past 24 hours in the painful areas of the feet from Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the endpoint, the change in worst pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline worst pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model." (NCT02068027)
Timeframe: The change from Baseline (worse over Day -14 to Day -8) to End-of-Treatment (worse over Days 78 to 84 [±3 days])

Interventionunits on a scale (Mean)
Clonidine Gel 0.1%-1.4
Placebo-1.4

Reviews

8 reviews available for clonidine and Chronic Pain

ArticleYear
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Topical clonidine for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2022, 05-19, Volume: 5

    Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con

2022
Strategies of analgesic treatment after cesarean delivery. Current state and new alternatives.
    Revista espanola de anestesiologia y reanimacion, 2020, Volume: 67, Issue:3

    Topics: Acetaminophen; Analgesia, Obstetrical; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia, Epi

2020
Chronic pain after childbirth.
    International journal of obstetric anesthesia, 2013, Volume: 22, Issue:2

    Topics: Acute Pain; Adrenergic alpha-Agonists; Adult; Amines; Analgesics; Anesthetics, Dissociative; Cesarea

2013
Intrathecal delivery of analgesics.
    Methods in molecular biology (Clifton, N.J.), 2014, Volume: 1141

    Topics: Analgesics, Opioid; Baclofen; Bupivacaine; Catheters, Indwelling; Chronic Pain; Clonidine; Drug Deli

2014
Non-surgical interventions for the management of chronic pelvic pain.
    The Cochrane database of systematic reviews, 2014, Mar-05, Issue:3

    Topics: Amines; Amitriptyline; Analgesics; Chronic Pain; Clonidine; Contraceptive Agents, Female; Cyclohexan

2014
Topical clonidine for neuropathic pain.
    The Cochrane database of systematic reviews, 2015, Aug-31, Volume: 8

    Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Analgesics; Chronic Pain; Clonidine;

2015
Clinical efficacy and safety of eperisone for low back pain: A systematic literature review.
    Pharmacological reports : PR, 2016, Volume: 68, Issue:5

    Topics: Chronic Pain; Clonidine; Humans; Low Back Pain; Pain Measurement; Propiophenones; Treatment Outcome

2016
Intentional intrathecal opioid detoxification in 3 patients: characterization of the intrathecal opioid withdrawal syndrome.
    Pain practice : the official journal of World Institute of Pain, 2013, Volume: 13, Issue:4

    Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; Clo

2013

Trials

4 trials available for clonidine and Chronic Pain

ArticleYear
Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome.
    Pain, 2015, Volume: 156, Issue:1

    Topics: Adenosine; Adult; Analgesics; Chronic Pain; Clonidine; Complex Regional Pain Syndromes; Cross-Over S

2015
Effect of adding cervical facet joint injections in a multimodal treatment program for long-standing cervical myofascial pain syndrome with referral pain patterns of cervical facet joint syndrome.
    Journal of anesthesia, 2012, Volume: 26, Issue:5

    Topics: Acetaminophen; Anesthetics, General; Chronic Pain; Clonidine; Codeine; Combined Modality Therapy; Do

2012
Eperisone versus tizanidine for treatment of chronic low back pain.
    Minerva medica, 2012, Volume: 103, Issue:3

    Topics: Analysis of Variance; Chronic Pain; Clonidine; Drug Therapy, Combination; Female; Humans; Italy; Low

2012
Effect of the addition of clonidine to locally administered bupivacaine on acute and chronic postmastectomy pain.
    Journal of clinical anesthesia, 2013, Volume: 25, Issue:1

    Topics: Acute Pain; Administration, Topical; Adult; Analgesics; Anesthetics, Local; Breast Neoplasms; Bupiva

2013

Other Studies

9 other studies available for clonidine and Chronic Pain

ArticleYear
Discovery of non-zwitterionic aryl sulfonamides as Na
    Bioorganic & medicinal chemistry, 2017, 10-15, Volume: 25, Issue:20

    Topics: Administration, Oral; Animals; Chronic Pain; Disease Models, Animal; Dose-Response Relationship, Dru

2017
Effectiveness of Ultrasound-Guided Canal Adductor Blockade for Chronic Pain and Functioning in Knee Osteoarthritis: A Prospective Longitudinal Observational Study.
    BioMed research international, 2022, Volume: 2022

    Topics: Activities of Daily Living; Aged; Analgesics; Anesthetics, Local; Chronic Pain; Clonidine; Disabilit

2022
Clonidine is better than zopiclone for insomnia treatment in chronic pain patients.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2022, 06-01, Volume: 18, Issue:6

    Topics: Adult; Azabicyclo Compounds; Chronic Pain; Clonidine; Cross-Over Studies; Humans; Hypnotics and Seda

2022
Multimodal intrathecal analgesia in refractory cancer pain.
    Scandinavian journal of pain, 2017, Volume: 14

    Topics: Aged; Analgesics; Bupivacaine; Cancer Pain; Chronic Pain; Clonidine; Female; Follow-Up Studies; Huma

2017
Trauma-induced adiposis dolorosa (Dercum's disease).
    BMJ case reports, 2018, Mar-28, Volume: 2018

    Topics: Accidents, Traffic; Adipose Tissue; Adiposis Dolorosa; Adult; Amitriptyline; Analgesics, Non-Narcoti

2018
Combined Superficial and Deep Serratus Plane Block With Bupivacaine, Dexamethasone, and Clonidine in the Treatment of a Patient With Postmastectomy Pain Syndrome: A Case Report.
    A&A practice, 2018, Nov-01, Volume: 11, Issue:9

    Topics: Adult; Analgesics; Anesthetics; Bupivacaine; Chronic Pain; Clonidine; Dexamethasone; Drug Therapy, C

2018
Topical combinations to treat microvascular dysfunction of chronic postischemia pain.
    Anesthesia and analgesia, 2014, Volume: 118, Issue:4

    Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Capillaries; Chemistry, Phar

2014
Intrathecal Clonidine Pump Failure Causing Acute Withdrawal Syndrome With 'Stress-Induced' Cardiomyopathy.
    Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2016, Volume: 12, Issue:1

    Topics: Adrenergic alpha-2 Receptor Agonists; Back Pain; Chronic Pain; Clonidine; Electrocardiography; Equip

2016
Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice.
    Neural plasticity, 2015, Volume: 2015

    Topics: Acetylcholinesterase; Alkaloids; Ambenonium Chloride; Analgesics; Animals; Atropine; Behavior, Anima

2015
chemdatabank.com